- Home
- HOWL vs VERU Comparison
HOWL vs VERU Comparison
Compare HOWL & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- VERU
- Stock Information
- Founded
- HOWL 2017
- VERU 1971
- Country
- HOWL United States
- VERU United States
- Employees
- HOWL N/A
- VERU N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- VERU Health Care
- Exchange
- HOWL Nasdaq
- VERU Nasdaq
- Market Cap
- HOWL 64.5M
- VERU 54.6M
- IPO Year
- HOWL 2021
- VERU 1990
- Fundamental
- Price
- HOWL $1.56
- VERU $3.50
- Analyst Decision
- HOWL Strong Buy
- VERU Strong Buy
- Analyst Count
- HOWL 5
- VERU 3
- Target Price
- HOWL $7.20
- VERU $33.33
- AVG Volume (30 Days)
- HOWL 1.3M
- VERU 143.2K
- Earning Date
- HOWL 11-14-2025
- VERU 12-15-2025
- Dividend Yield
- HOWL N/A
- VERU N/A
- EPS Growth
- HOWL N/A
- VERU N/A
- EPS
- HOWL N/A
- VERU N/A
- Revenue
- HOWL N/A
- VERU $16,886,419.00
- Revenue This Year
- HOWL N/A
- VERU N/A
- Revenue Next Year
- HOWL N/A
- VERU N/A
- P/E Ratio
- HOWL N/A
- VERU N/A
- Revenue Growth
- HOWL N/A
- VERU 337.24
- 52 Week Low
- HOWL $0.60
- VERU $2.64
- 52 Week High
- HOWL $2.96
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- HOWL 45.71
- VERU 41.79
- Support Level
- HOWL $1.55
- VERU $3.69
- Resistance Level
- HOWL $1.83
- VERU $3.99
- Average True Range (ATR)
- HOWL 0.13
- VERU 0.31
- MACD
- HOWL -0.03
- VERU -0.12
- Stochastic Oscillator
- HOWL 14.71
- VERU 0.00
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.